An end-to-end approach to managing wearable medical devices through clinical development.
Navigating the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.
As the industry moves forward with the adoption of digital health technologies, using more Real World Evidence and hybrid virtual / decentralised clinical trials, eCOA and digital endpoints will become a necessity for clinical trials. In particular, clinical trials in cardiovascular, diabetes, rare diseases and neurodegenerative ailments such as Parkinson's disease and alzheimer's will benefit from advances in, and adoption of, digital endpoints.
As the Internet of Medical Things (IoMT) becomes increasingly used in clinical trial protocols, early adopters willing to invest in these technologies may win market share, while those without sufficient investments may find themselves at a disadvantage.
In this whitepaper we discuss a framework for integrating digital health effectively and efficiently:
The whitepaper will explore the challenges and weaknesses in using digital endpoints, and how digital endpoints can be successfully incorporated in a trial or observational study.